Management of acute attacks of hereditary angioedema: potential role of icatibant

Icatibant (Firazyr(®)) is a novel subcutaneous treatment recently licensed in the European Union for acute hereditary angioedema. Hereditary angioedema, resulting from inherited partial C1 inhibitor deficiency, is a disabling condition characterized by intermittent episodes of bradykinin-mediated an...

Descripción completa

Detalles Bibliográficos
Autor principal: Longhurst, Hilary J
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941790/
https://www.ncbi.nlm.nih.gov/pubmed/20859548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941790/
https://www.ncbi.nlm.nih.gov/pubmed/20859548

Ejemplares similares